Classical Hodgkin LymphomaSymptoms, Doctors, Treatments, Advances & More
Learn About Classical Hodgkin Lymphoma
Condition 101 content is not available at this time, but we are continually updating the site. Please check back.
However, there may be experts who have treated this or similar conditions in our Find a Doctor section and research may be available in our Latest Advances section.
Emory Winship Cancer Institute
Kristie Blum is a Hematologist Oncology provider practicing medicine in Atlanta, Georgia. She has been practicing medicine for over 29 years. Dr. Blum is rated as an Elite provider by MediFind in the treatment of Classical Hodgkin Lymphoma. She is also highly rated in 20 other conditions, according to our data. Her clinical expertise encompasses Mantle Cell Lymphoma (MCL), Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Bone Marrow Transplant, and Bone Marrow Aspiration. Dr. Blum is board certified in American Board Of Internal Medicine, 2004.
Emory Winship Cancer Institute
Jonathon Cohen is a Hematologist Oncology provider practicing medicine in Atlanta, Georgia. He has been practicing medicine for over 19 years. Dr. Cohen is rated as an Elite provider by MediFind in the treatment of Classical Hodgkin Lymphoma. He is also highly rated in 26 other conditions, according to our data. His clinical expertise encompasses Mantle Cell Lymphoma (MCL), Non-Hodgkin Lymphoma, B-Cell Lymphoma, Bone Marrow Transplant, and Vitrectomy. Dr. Cohen is board certified in American Board Of Internal Medicine, 2014.
Cleveland Clinic Main Campus
Paolo Caimi is a Hematologist Oncology specialist and a Hematologist practicing medicine in Cleveland, Ohio. Dr. Caimi is rated as an Elite provider by MediFind in the treatment of Classical Hodgkin Lymphoma. He is also highly rated in 37 other conditions, according to our data. His clinical expertise encompasses Non-Hodgkin Lymphoma, Diffuse Large B-Cell Lymphoma (DLBCL), B-Cell Lymphoma, Bone Marrow Transplant, and Bone Marrow Aspiration. Dr. Caimi is board certified in American Board Of Internal Medicine, 2011.
Summary: Patients in this prospective multicenter phase II study will be randomized between two first-line therapy strategies for advanced stages of cHL. In the Nivo-AVD cohort, patients will receive 2 cycles of nivolumab monotherapy followed by a switch to Nivo-AVD combination therapy (total of 6 cycles); in the Standard cohort, patients will receive therapy according to current clinical guidelines in Rus...
Summary: Generally, pediatric patients tolerate acute toxicities but are vulnerable to late effects. Thus, increasing chemotherapy intensity to achieve more rapid complete early response to limit radiation therapy is worth testing. In this CCCG-HL-2024 study, Brentuximab vedotin (Bv) was used to replace VCR and bleomycin in the ABVE-PC regimen in the previous CCCG-HD-2018 study, respectively, to form a Bv-...